These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32527461)

  • 21. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y
    Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
    Burger AM; Fiebig HH; Stinson SF; Sausville EA
    Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Encapsulation of the HSP-90 Chaperone Inhibitor 17-AAG in Stable Liposome Allow Increasing the Therapeutic Index as Assessed,
    Petersen ALOA; Campos TA; Dantas DADS; Rebouças JS; da Silva JC; de Menezes JPB; Formiga FR; de Melo JV; Machado G; Veras PST
    Front Cell Infect Microbiol; 2018; 8():303. PubMed ID: 30214897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Biosynthesis of a new psoralidin glucoside by enzymatic glycosylation].
    Li J; Li N; Zhao YR; Dai YQ; Huo Q; Ma T; Li HM; Wu CZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Aug; 36(8):1029-33. PubMed ID: 27578568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular characterization of macbecin as an Hsp90 inhibitor.
    Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
    J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
    Pelicano H; Carew JS; McQueen TJ; Andreeff M; Plunkett W; Keating MJ; Huang P
    Leukemia; 2006 Apr; 20(4):610-9. PubMed ID: 16482209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
    Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
    Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
    Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library.
    Eichner S; Knobloch T; Floss HG; Fohrer J; Harmrolfs K; Hermane J; Schulz A; Sasse F; Spiteller P; Taft F; Kirschning A
    Angew Chem Int Ed Engl; 2012 Jan; 51(3):752-7. PubMed ID: 22135226
    [No Abstract]   [Full Text] [Related]  

  • 33. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
    J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway.
    Ye XY; Luo QQ; Xu YH; Tang NW; Niu XM; Li ZM; Shen SP; Lu S; Chen ZW
    J Cell Mol Med; 2015 Mar; 19(3):651-63. PubMed ID: 25712415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anticancer effect of 17-(6-cinnamamido-hexylamino-)-17-demethoxygeldanamycin: in vitro and in vivo].
    Li L; Liu H; Zhang SH; Hu L; Zhen YS
    Yao Xue Xue Bao; 2013 Dec; 48(12):1771-7. PubMed ID: 24689233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
    Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
    Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
    Johnson AJ; Wagner AJ; Cheney CM; Smith LL; Lucas DM; Guster SK; Grever MR; Lin TS; Byrd JC
    Br J Haematol; 2007 Dec; 139(5):837-44. PubMed ID: 17949452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.
    Zhang H; Neely L; Lundgren K; Yang YC; Lough R; Timple N; Burrows F
    Int J Cancer; 2010 Mar; 126(5):1226-34. PubMed ID: 19676042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
    Banerji U; Sain N; Sharp SY; Valenti M; Asad Y; Ruddle R; Raynaud F; Walton M; Eccles SA; Judson I; Jackman AL; Workman P
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):769-78. PubMed ID: 18193424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
    Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
    Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.